Danosfloxacin — Veterinary Vademecum Drug Reference

Dosage & Administration Guidelines

Species	Route	Dose	Frequency	Duration & Clinical Notes
Dog	PO	2.5-5 mg/kg	q24h	Duration: 5-14 days depending on infection Notes: For urinary tract infections, 3-5 days may suffice; for deep pyoderma, up to 28 days.
Cat	PO	2.5-5 mg/kg	q24h	Duration: 5-14 days Notes: Use with caution in young kittens due to potential cartilage effects.
Horse	IV	5 mg/kg	q24h	Duration: 5-10 days Notes: Oral absorption is variable; IV preferred for severe infections.
Cattle	SC	2.5-5 mg/kg	q24h	Duration: 3-5 days Notes: For BRD, a single dose of 7.5 mg/kg may be used in some formulations.
Small Ruminants	PO	2.5-5 mg/kg	q24h	Duration: 3-5 days Notes: Extra-label use; observe withdrawal times.
Rabbit	PO	5-10 mg/kg	q24h	Duration: 5-7 days Notes: May cause GI upset; monitor for diarrhea.
Poultry	PO (drinking water)	10 mg/kg	q24h	Duration: 3-5 days Notes: Ensure adequate water intake; adjust for body weight.
Reptiles	PO or IM	5-10 mg/kg	q24-48h	Duration: 7-14 days Notes: Dosing based on limited studies; adjust based on species and temperature.

Clinical Indications & Species Uses

General Indications

Broad-spectrum antibacterial for susceptible infections

Dog (Canine)

Treatment of urinary tract infections
Skin and soft tissue infections
Respiratory tract infections (e.g., pneumonia, bronchitis)
Prostatitis
Wound infections

Cat (Feline)

Treatment of urinary tract infections
Skin and soft tissue infections
Respiratory tract infections
Abscesses

Horse (Equine)

Treatment of respiratory tract infections (e.g., pneumonia, pleuropneumonia)
Urinary tract infections
Skin and soft tissue infections
Septicemia

Cattle (Bovine)

Treatment of bovine respiratory disease (BRD)
Metritis
Mastitis (in some countries)
Foot rot

Small Ruminants (Sheep / Goat)

Treatment of respiratory infections
Enteritis
Mastitis (extra-label)

Rabbit & Small Mammals

Treatment of respiratory infections (e.g., Pasteurellosis)
Urinary tract infections
Skin infections

Avian & Poultry

Treatment of colibacillosis
Mycoplasmosis
Respiratory infections
Enteritis

Exotic & Other Species

Treatment of bacterial infections in reptiles (e.g., shell rot)
Small mammals (e.g., ferrets, guinea pigs) for respiratory and urinary infections

Pharmacology & Mechanism of Action

Drug Class: Fluoroquinolone antibiotic | Pharmacological Group: Antibacterial

Mechanism of Action: Danosfloxacin is a fluoroquinolone antibacterial agent that inhibits bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, enzymes essential for DNA replication, transcription, repair, and recombination. By binding to these enzymes, it prevents the supercoiling and uncoiling of bacterial DNA, leading to rapid bacterial cell death. It is bactericidal and exhibits concentration-dependent killing.

Pharmacodynamics: Danosfloxacin has a broad spectrum of activity against Gram-positive and Gram-negative bacteria, including some anaerobes. It is particularly effective against Enterobacteriaceae, Pasteurella spp., Mycoplasma spp., and some staphylococci. Its activity is enhanced by its ability to penetrate tissues and cells, achieving high intracellular concentrations. The post-antibiotic effect is prolonged, allowing for once-daily dosing in some species.

⚡ Pharmacokinetics Summary

Absorption: Danosfloxacin is well absorbed after oral administration in most species, with bioavailability ranging from 70-100% depending on species and formulation. Absorption is slightly delayed by food but not significantly reduced.

Distribution: Danosfloxacin has a large volume of distribution, penetrating well into tissues, including lung, skin, urinary tract, and prostate. It achieves high concentrations in macrophages and polymorphonuclear leukocytes. Protein binding is low to moderate (20-30%) in most species.

Metabolism: Danosfloxacin undergoes minimal hepatic metabolism. The primary metabolic pathways are glucuronidation and N-dealkylation, but the parent compound is largely excreted unchanged.

Excretion: Excretion is primarily renal (glomerular filtration and tubular secretion) and biliary. In dogs and cats, approximately 50-70% of the drug is excreted unchanged in urine, with the remainder in feces. In ruminants, biliary excretion is more significant.

Half-Life: Dog: 6-8 hours; Cat: 8-10 hours; Horse: 4-6 hours; Cattle: 2-4 hours; Poultry: 4-6 hours.

Bioavailability: Oral: 80-100% in dogs and cats; 70-90% in horses; 60-80% in cattle and poultry.

Protein Binding: 20-30% in most species, but may be higher in some (e.g., 40% in horses).

Available Formulations & Strengths

Oral Tablet 50 mg, 150 mg, 300 mg (PO)

Oral Solution 25 mg/mL (PO)

Injectable Solution 100 mg/mL (IV, SC)

Contraindications & Clinical Warnings

Contraindications:

Hypersensitivity to fluoroquinolones
Young growing animals (especially dogs and cats under 8 months; large breeds under 18 months) due to risk of arthropathy
Pregnancy and lactation (unless benefits outweigh risks)
Known cartilage lesions or joint disease
Concurrent use with theophylline (may increase theophylline levels)

Warnings & Clinical Precautions:

Use with caution in animals with renal or hepatic impairment; dose adjustment may be necessary.
In horses, oral administration may cause diarrhea; monitor for GI disturbances.
In ruminants, rapid IV administration may cause cardiovascular collapse; administer slowly.
May cause photosensitivity; avoid excessive sunlight exposure during treatment.
Use in food animals must comply with withdrawal times and extra-label regulations.
Fluoroquinolones may cause CNS stimulation; use with caution in animals with seizure disorders.

Adverse Effects & Reactions

Common:

Gastrointestinal upset (vomiting, diarrhea, anorexia)
Injection site reactions (pain, swelling)
Elevated liver enzymes (transient)

Serious / Severe:

Cartilage damage in young animals
CNS signs (seizures, ataxia, agitation)
Acute renal failure (rare)
Tendon rupture (rare)
Anaphylaxis (rare)

Rare:

Blood dyscrasias (leukopenia, thrombocytopenia)
Hepatotoxicity
Crystalluria
Ocular toxicity (with high doses)

Key Drug Interactions

Interacting Drug / Class	Clinical Effect & Mechanism	Severity
Antacids (aluminum, magnesium, calcium)	Reduced absorption of danosfloxacin due to chelation; separate administration by 2-4 hours.	High
Sucralfate	Reduced absorption; separate administration by 2-4 hours.	High
Theophylline	Increased theophylline levels, risk of toxicity; monitor levels.	Moderate
Warfarin	Increased anticoagulant effect; monitor coagulation.	Moderate
NSAIDs (e.g., flunixin, carprofen)	Increased risk of CNS stimulation and seizures; use with caution.	Moderate
Corticosteroids	Increased risk of tendon rupture; avoid concurrent use.	High

Overdose & Toxicity Management

Signs of Toxicity:

Vomiting
Diarrhea
CNS signs (tremors, seizures, depression)
Arthrotoxicity in young animals
Renal toxicity (crystalluria, acute renal failure)

Emergency Treatment Protocol: Induce emesis if recent oral ingestion. Administer activated charcoal to reduce absorption. Provide supportive care: IV fluids to maintain hydration and promote excretion. Control seizures with diazepam or barbiturates. Monitor renal and hepatic function. There is no specific antidote.

Food Animal Withdrawal Times

🥩 Meat: 5 days🥛 Milk: 3 days🥚 Eggs: 5 days

Withdrawal times may vary by country and formulation; always follow local regulations. For extra-label use, extend withdrawal periods.

Storage, Handling & Regulatory Information

Storage Temperature: Store at controlled room temperature 20-25°C (68-77°F), excursions permitted between 15-30°C (59-86°F).

Light Sensitivity: Light-sensitive — protect from direct exposure.

Handling & Special Conditions: Protect from light and moisture. Keep in tightly closed container. Do not freeze injectable solutions.

Dispensing Status: Prescription Required (Rx Only)

Approval Status: Approved for use in dogs and cats in the US; not approved for food animals in the US. Approved for cattle and poultry in some other countries.

Extra-Label (Off-Label) Use: In the US, extra-label use of fluoroquinolones in food animals is prohibited by the FDA (except for specific approved indications). In other countries, extra-label use may be allowed under veterinary oversight with extended withdrawal times.

Clinical Pearls & Practice Notes

💡 Clinical Insights: Danosfloxacin is a broad-spectrum fluoroquinolone with excellent tissue penetration and a long half-life, allowing once-daily dosing. It is particularly useful for respiratory, urinary, and skin infections. In dogs and cats, it is generally well tolerated, but caution is needed in young animals due to cartilage effects. In horses, oral absorption is variable, so parenteral administration is preferred for severe infections. For food animals, strict adherence to withdrawal times is essential. Always perform culture and sensitivity testing when possible to ensure appropriate use and minimize resistance development. Monitor for adverse effects, especially GI and CNS signs.

References & Literature

📚 Plumb's Veterinary Drug Handbook
📚 Papich Veterinary Pharmacology and Therapeutics
📚 Compendium of Veterinary Products (CVP)